Allogeneic Natural Killer (NK) Cells in Patients With Advanced Metastatic Breast Cancer

Allogeneic Natural Killer Cells in Patients With Advanced Metastatic Breast Cancer

RATIONALE: Giving chemotherapy before a donor natural killer (NK) cell infusion helps stop the growth of tumor cells. It also helps stop the patient's immune system from rejecting the donor's cells. Giving NK cells from a related donor may kill the tumor cells.

PURPOSE: This study furthers the research of previous studies (MT2003-01 and MT2004-25) which were to determine a specific preparatory regimen (cyclophosphamide and fludarabine) could create an environment in which infused NK cells can grow and effectively treat patients with relapsed AML. This study will test the previous regimen in patients with breast cancer.

Study Overview

• Status: Terminated
• Conditions: Breast Cancer
• Intervention / Treatment: Drug: Fludarabine; Drug: Cyclophosphamide; Radiation: Total body irradiation; Other: Natural killer cell infusion; Biological: Interleukin-2

Detailed Description

We believe that administration of related allogeneic (donor) natural killer cells along with IL-2, rather than autologous natural killer cells will provide the most effective anticancer therapy in this setting, and wish to test this approach. To do this, we will select a related donor who is partially HLA-matched with the study subject, to increase the likelihood that donor natural killer cells will kill the subject's cancer cells. We will also give chemotherapy drugs to increase the subject's tolerance for the donor natural killer cells. We will test the use of donor natural killer (NK) cell infusions. The immune system has a special way that it sees and identifies cancer cells or foreign agents (like viruses). The subject's own NK cells may not attack their cancer because NK cells see the tumor cells as "self" (a coating on the cell surface identifies a cell as "self" or "non-self"). We have reason to believe that NK cells may not kill cancer cells because NK cells have special receptors that "turn them off" when they encounter cancer cells (by seeing them as "self"). We may be able to get around this problem by using donor NK cells. Finally, subjects will receive a dose of subcutaneous IL-2 3 times a week (for 2 weeks) which has been proven safe in our previous studies to stimulate the natural killer cells.

• Study Type: Interventional
• Enrollment (Actual): 6
• Phase: Phase 2

Contacts and Locations

Study Locations

• United States
  • Minnesota
    • Minneapolis, Minnesota, United States, 55455
      • Masonic Cancer Center at University of Minnesota

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion criteria:

• Diagnosis of metastatic breast cancer that has progressed on or failed at least one salvage chemotherapy regimen for metastatic disease and that meets the following disease specific related criteria:

  • Measureable metastatic disease per Response Evaluation Criteria In Solid Tumor (RECIST) - bone only not eligible.
  • Disease progression while receiving prior therapy with a hormonal agent (if estrogen/progesterone receptor-positive) and/or trastuzumab (Herceptin®) (if HER2-neu positive)
  • Brain metastases allowed provided they are stable for ≥ 3 months after prior treatment
• Related HLA-haploidentical natural killer cell donor available (by ≥ class I serologic typing)
• Male or female
• Performance status 50-100%
• Platelet count ≥ 80,000/mm³ (unsupported by transfusions)
• Hemoglobin ≥ 9 g/dL (unsupported by transfusions)
• Absolute neutrophil count ≥ 1,000/mm³ (unsupported by sargramostim [GM-CSF] or filgrastim [G-CSF])
• Creatinine ≤ 2.0 mg/dL
• Liver function tests < 5 times normal
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception
• LVEF > 40%*
• Pulmonary function > 50%* (DLCO corrected AND FEV_1)
• No active infection (i.e., afebrile, off antibiotics, and no uninvestigated radiologic lesions)

Exclusion Criteria:

• At least 3 days since prior prednisone or other immunosuppressive medications
• No other concurrent therapy for cancer

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm

Intervention / Treatment

Experimental: All Treated Patients; All patients with advanced metastatic breast cancer treated with natural killer cells after receiving fludarabine, cyclosphosphamide and total body irradiation.

Drug: Fludarabine; administered intravenously 25 mg/m^2 times 5 doses; Other Names: Fludara; Drug: Cyclophosphamide; administered intravenously 60 mg/kg days times 2 doses.; Other Names: Endoxan, Cytoxan, Neosar, Procytox; Radiation: Total body irradiation; 200 cGy (gray) on day -1; Other Names: radiation; Other: Natural killer cell infusion; Infused cell dose is within the range of 1.5-8.0 x 10^7/kg. Cell counts are based on total cells infused after the activation culture and washing determined on the morning of infusion.; Other Names: NK cells; Biological: Interleukin-2; administered subcutaneously (10 MU) 3 times per week for 6 doses; Other Names: IL-2

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of Patients Who Had Expansion of Natural Killer Cells	Successful Natural Killer (NK) cell expansion is defined as detection of an absolute circulating donor-derived NK cell count of >100 cells/ul of whole blood 14 days after infusion with <5% donor T and B cells in mononuclear population (in metastatic breast cancer patients).	Day 14

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of Patients by Disease Response	Defined by the Response Evaluation Criteria in Solid Tumors (RECIST) criteria: Complete Response (CR: Disappearance of all target lesions; Partial Response (PR): At least a 30% decrease in the sum of the longest diameter (LD) of target lesions; Stable Disease (SD): Neither sufficient shrinkage to qualify for PR or sufficient increase to qualify for PD; Progressive Disease (PD): At least a 20% increase in the sum of the LD of target lesions of appearance of one or more new lesions of clinical benefit (CB; stable disease for greater than 6 months.	6 Months, 1 Year
Number of Patients Who Died While on Study	Number of patients who died within 100 days and after 100 days of natural killer (NK) treatment with or without total body irradiation.	Within 100 days, After 100 days
Overall Median Number of Days Patients Alive After Treatment	Calculated median number of days of survival (patients alive days after treatment).	First Day of Treatment Until Death

Collaborators and Investigators

• Sponsor: Masonic Cancer Center, University of Minnesota
• Investigators: Study Chair: Jeffrey Miller, MD, Masonic Cancer Center, University of Minnesota; Principal Investigator: Sarah Cooley, MD, Masonic Cancer Center, University of Minnesota

Study record dates

Study Major Dates

• Study Start: April 1, 2006
• Primary Completion (Actual): September 1, 2009
• Study Completion (Actual): January 1, 2010

Study Registration Dates

• First Submitted: September 13, 2006
• First Submitted That Met QC Criteria: September 13, 2006
• First Posted (Estimate): September 15, 2006

Study Record Updates

• Last Update Posted (Actual): December 28, 2017
• Last Update Submitted That Met QC Criteria: December 3, 2017
• Last Verified: December 1, 2017

More Information

Terms related to this study

• Keywords: stage IV breast cancer; recurrent breast cancer; male breast cancer
• Additional Relevant MeSH Terms: Skin Diseases; Neoplasms; Neoplasms by Site; Breast Diseases; Breast Neoplasms; Physiological Effects of Drugs; Molecular Mechanisms of Pharmacological Action; Peripheral Nervous System Agents; Analgesics; Sensory System Agents; Analgesics, Non-Narcotic; Antirheumatic Agents; Antineoplastic Agents; Immunosuppressive Agents; Immunologic Factors; Antineoplastic Agents, Alkylating; Alkylating Agents; Myeloablative Agonists; Cyclophosphamide; Fludarabine; Interleukin-2
• Other Study ID Numbers: UMN-2005LS033; UMN-0505M70037 (Other Identifier: IRB, University of Minnesota); UMN-MT2005-08 (Other Identifier: Blood and Bone Marrow Transplantation Program)